Qingdao Vland Biotech Inc(603739) 4 issued the annual report for 2021 on April 19. During the reporting period, the company achieved an operating revenue of 1.151 billion yuan, a year-on-year increase of 19.85%; The net profit attributable to the shareholders of the listed company was 133 million yuan, with a year-on-year increase of 21.65%, and the basic earnings per share was 0.54 yuan. The company plans to distribute a cash dividend of 1.6 yuan (including tax) for every 10 shares to all shareholders.
The company disclosed the first quarter report of 2022 on the same day. During the reporting period, the company realized an operating revenue of 256 million yuan, a net profit of 180839 million yuan attributable to the shareholders of the listed company and a basic earnings per share of 0.07 yuan.
leading products drive performance growth
The company is mainly engaged in the R & D, production and sales of enzyme preparations, probiotics and animal health products. During the reporting period, the rapid growth of enzyme preparation and micro ecological business was the main driving force for the growth of the company’s revenue and profit. In 2021, the sales volume of the company’s enzyme preparation sector reached 16200 tons, with a year-on-year increase of 35.02%; The operating revenue reached 430 million yuan, a year-on-year increase of 38.89%. The annual sales volume of micro ecology was 27300 tons, with a year-on-year increase of 19.09%; The operating revenue was 250 million yuan, a year-on-year increase of 16.58%.
The company is an obvious beneficiary of the feed prohibition order. As a bio high-tech enterprise with great research and development advantages in the field of enzyme preparations and microecological preparations, Qingdao Vland Biotech Inc(603739) prospectively arranged the research and development of antibiotic substitution products, constructed a systematic antibiotic substitution scheme, and formed a vland-pcp (accurate customization platform based on feed enzyme application big data system) to accurately customize enzymes, glucose oxidase, mycotoxin degrading enzyme, lysozyme and other enzyme preparations, probiotics The diversified alternative product solutions with plant extracts as the core have formed a comprehensive service system linking feed end, breeding end and food end.
In addition, the application of unconventional raw materials has also driven the growth of feed enzymes. Under the background that the prices of feed raw materials such as corn and soybean meal have been at a high level for a long time, the losses of the aquaculture industry continue to intensify and the capital chain continues to be tight, the development of alternative products of feed raw materials has gradually developed into a rigid demand. In March 2021, the Ministry of agriculture and rural areas issued the work plan for reduction and substitution of corn and soybean meal in feed to speed up the reduction and substitution process of corn and soybean meal and further promote the application of unconventional raw materials. Among them, enzyme preparation is a crucial link in the development of new feed raw materials instead of soybean protein, fermented protein raw materials and protein raw materials from microorganisms.
The annual report shows that the company’s research accumulation on unconventional raw materials for many years has helped the perfect replacement of feed raw materials. Vland-pcp customized enzyme solution platform of the company can effectively solve the problems of digestion, absorption and processing of unconventional raw materials, improve feed conversion efficiency and enhance the growth performance of livestock and poultry. The platform has been recognized by many major customers, and its recognition continues to improve.
human probiotic strategy set sail
While the traditional business grew steadily, the company also launched the human probiotic project in 2021. Probiotics can adjust human physiological functions, improve intestinal flora balance and improve body immunity. They are widely used in food, health care products, skin care products and other fields. They have broad market prospects and development prospects. The scale of products will be close to 85 billion yuan in 2020.
According to the industry situation of human probiotics and the development strategy of the company, the company adjusted the business plan of human probiotics business. The company terminated the implementation of the technical transformation project of functional edible probiotic series products with an annual output of 1000 tons, and instead carried out the business through cooperation with international giants. During the reporting period, Weifang weizhilan Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, introduced international investor ADM Singapore through capital increase to jointly expand the industrial chain of probiotics for human use. The products are promoted to the global market and are expected to be put into production and operation by the end of 2023.
Based on the original research and development strength of animal and plant microecology, the company has established the nutrition and health technology center. At present, it has formed four research and development platforms of strain identification, function verification, analysis and screening and strain improvement, and developed 16 probiotic strains with independent intellectual property rights, including alleviating gastrointestinal discomfort, improving skin condition, delaying aging, enhancing bone health, enhancing immune function Prevention of upper respiratory tract infection and anti-bacterial and anti-inflammatory. 38 invention patents related to probiotics, 12 utility model patents and 3 PCT patents have been applied. At present, 11 patents have been authorized, covering probiotic dietary supplements, functional raw materials of skin care products, food safety prediction technology and product application design innovation.
continuously high proportion of R & D investment
Technological innovation is the core strategy of the company. In 2021, the company officially launched the “ecological innovation” strategy, breaking external boundaries and establishing broader links and cooperation based on the platform based innovation system; Taking Qingdao innovation center as the starting point, technological innovation centers such as Shanghai, Wuxi and Tianjin will be established one after another to form an open innovation ecosystem.
According to the annual report, the company’s R & D expenses in 2021 were 101 million yuan, with a year-on-year increase of 26.31%, accounting for 8.77% of the operating revenue, which continued to be at a high level in the industry. In 2021, the company added 34 Chinese authorized invention patents, 2 American patents, 1 European Patent and 4 PCT international applications. By the end of the reporting period, the company and its subsidiaries had 284 authorized invention patents in China, 7 authorized patents in the United States, 2 authorized patents in Europe, 19 PCT international applications and 37 new veterinary drug registration certificates (including 3 national class I new veterinary drugs). The company’s R & D investment in the field of animal protection has achieved results. In recent ten years, the total number of new veterinary drugs registered by the company ranks among the top five in the animal protection industry, including the second in the number of new veterinary drugs registered in Chinese veterinary drugs and the top five in the number of new veterinary drugs registered in chemical drugs.
Looking forward to the future, the company said it would continue to focus on its core business, take the platform based management system as the main body, focus on technological innovation and global layout, form a new development pattern of “one body and two wings”, and build itself into an industrial biological platform company driven by technological innovation and globalization.
